HomeQuestion

Would you hold off using fam-trastuzumab deruxtecan-nxki (Enhertu) in malignant pleural effusion?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In a patient with de novo stage IV breast carcinoma harboring an RB1 Q395* (nonsense) mutation, would treatment with a CDK4/6 inhibitor be appropriate, or should it be avoided due to likely resistance?

What are your top takeaways in Breast Cancer from ESMO 2025?

What are your top takeaways in Radiation Oncology from SABCS 2025?

How do you approach second-line therapy for patients with PD-L1 positive metastatic TNBC, after progression on sacituzumab govitecan + pembrolizumab?

For a patient with ER+, HER2-low leptomeningeal disease, but no other sites of metastatic disease, what treatments would you consider after trastuzumab deruxtecan?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.